Participant flow14

How many started, completed or left each group, period by period.

1 to 14 of 14

Period	Milestone	Group	Participants
Randomized to Study Treatment	STARTED	Exemestane	4,904
Randomized to Study Treatment	STARTED	Tamoxifen Followed by Exemestane	4,875
Randomized to Study Treatment	COMPLETED	Exemestane	4,898
Randomized to Study Treatment	COMPLETED	Tamoxifen Followed by Exemestane	4,868
Randomized to Study Treatment	NOT COMPLETED	Exemestane	6
Randomized to Study Treatment	NOT COMPLETED	Tamoxifen Followed by Exemestane	7
Study Treatment to 5 Year Report	STARTED	Exemestane	4,898
Study Treatment to 5 Year Report	STARTED	Tamoxifen Followed by Exemestane	4,868
Study Treatment to 5 Year Report	Treated	Exemestane	4,852
Study Treatment to 5 Year Report	Treated	Tamoxifen Followed by Exemestane	4,814
Study Treatment to 5 Year Report	COMPLETED	Exemestane	2,333
Study Treatment to 5 Year Report	COMPLETED	Tamoxifen Followed by Exemestane	1,380
Study Treatment to 5 Year Report	NOT COMPLETED	Exemestane	2,565
Study Treatment to 5 Year Report	NOT COMPLETED	Tamoxifen Followed by Exemestane	3,488

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00036270/flow